Open AccessGeneralizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer
Author(s) -
Misako Nagasaka,
Cliff Molife,
Zhanglin Lin Cui,
Victoria Jennifer Stefaniak,
Xiaohong Li,
Sangmi Kim,
Hsui-Yung Lee,
Julia Beyrer,
George R. Blumenschein
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0099
Subject(s) - medicine , lung cancer , population , oncology , pemetrexed , clinical trial , cohort , chemotherapy , environmental health , cisplatin
Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient’s contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.